Nov 04, 2020 5:05pm EST Updated Clinical Data From Phase 2 SPiReL Study Evaluating IMV’s T Cell Therapy in Combination With Merck’s Keytruda® in Patients With r/r DLBCL to Be Presented at The American Society of Hematology Annual Meeting
Oct 29, 2020 7:05am EDT IMV Inc. to Report Third Quarter 2020 Results and Present Biomarkers Associated With Clinical Response in Patients With r/r DLBCL treated with DPX-Survivac Combination Therapy
Oct 15, 2020 7:05am EDT Biomarkers Associated With Clinical Response in Patients With r/r DLBCL Treated With DPX-Survivac Combination Therapy to be Presented at the Upcoming Annual SITC Meeting
Sep 16, 2020 7:05am EDT IMV CEO to Participate at the Vaccines Panel of the Sachs Associates 20th Annual Biotech in Europe Forum
Aug 05, 2020 7:05am EDT IMV Receives Funding From Canadian Governmental Agencies for COVID-19 Vaccine Phase 1 Clinical Study
Aug 03, 2020 7:05am EDT IMV Inc. to Announce Second Quarter 2020 Results and Host a Conference Call and Webcast on August 12, 2020
